Microport Scientific Corp
HKEX:853
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Microport Scientific Corp
Net Issuance of Debt
Microport Scientific Corp
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Microport Scientific Corp
HKEX:853
|
Net Issuance of Debt
$43.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Net Issuance of Debt
¥3.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Net Issuance of Debt
-¥5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
Net Issuance of Debt
¥1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
62%
|
CAGR 10-Years
62%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Net Issuance of Debt
¥385.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Microport Scientific Corp
Glance View
MicroPort Scientific Corporation, a burgeoning force in the medical devices industry, has carved a niche for itself as an innovative leader headquartered in the bustling city of Shanghai, China. Founded in 1998, the company embarked on its mission to enhance lives by providing cutting-edge medical solutions. Operating in diverse fields such as cardiovascular, orthopedics, endovascular, and neurovascular, MicroPort thrives on its commitment to developing innovative products. The cornerstone of its business model is its robust research and development infrastructure, which fuels a pipeline of new products and drives advancements in medical technology. By leveraging strategic partnerships and acquisitions, MicroPort continually expands its capabilities, tapping into global expertise and elevating its standing in the competitive landscape. The company's revenue model is built upon the sale and distribution of high-performance medical devices across various international markets. Through a vast network of distributors and direct sales teams, MicroPort targets hospitals, clinics, and healthcare providers. Its portfolio includes stents for cardiovascular needs, orthopedic implants, and pacemakers, each designed to address specific therapeutic requirements. The firm's strategic emphasis on innovation, manufacturing prowess, and quality assurance augments its ability to meet rising healthcare demands globally. By focusing on solutions that improve patient outcomes and streamline healthcare delivery, MicroPort not only reinforces its market presence but also captures a significant market share. Thus, through its dual focus on expanding its technological offerings and growing its global footprint, MicroPort sustains its economic engine and continues its trajectory of consistent growth.
See Also
What is Microport Scientific Corp's Net Issuance of Debt?
Net Issuance of Debt
43.2m
USD
Based on the financial report for Dec 31, 2025, Microport Scientific Corp's Net Issuance of Debt amounts to 43.2m USD.
What is Microport Scientific Corp's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-43%
Over the last year, the Net Issuance of Debt growth was 108%. The average annual Net Issuance of Debt growth rates for Microport Scientific Corp have been -43% over the past three years .